Molecular Partners AG Files 6-K with H1 2025 Financials

TL;DR

MPWR 6-K dropped: H1 2025 financials out, showing capital and earnings details. Check it.

AI Summary

Molecular Partners AG filed a 6-K report on August 25, 2025, for the period ending June 30, 2025. The filing includes financial data for the first half of 2025 and the full year 2024, detailing issued capital, additional paid-in capital, treasury shares, and retained earnings. The company is based in Zurich-Schlieren, Switzerland, and operates in the biological products sector.

Why It Matters

This filing provides investors with an update on Molecular Partners AG's financial position as of mid-2025, crucial for assessing the company's stability and performance.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) providing standard financial data and does not indicate any unusual events or significant changes.

Key Numbers

• 2025 Q2 — Reporting Period (Financial data covers the second quarter of 2025.)
• 2024-12-31 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

• Molecular Partners AG (company) — Filer of the report
• 0001745114-25-000031 (filing_id) — Accession number for the filing
• 20250825 (date) — Filing date
• 20250630 (date) — Period of report
• Zurich-Schlieren (location) — Company's business address

FAQ

Filing Documents

• moln-20250630.htm (6-K) — 436KB
• a20250825molecularpartners.htm (EX-99.1) — 34KB
• image_0a.jpg (GRAPHIC) — 19KB
• moln-20250630_g1.jpg (GRAPHIC) — 12KB
• moln-20250630_g2.jpg (GRAPHIC) — 45KB
• moln-20250630_g3.jpg (GRAPHIC) — 7KB
• 0001745114-25-000031.txt ( ) — 2397KB
• moln-20250630.xsd (EX-101.SCH) — 30KB
• moln-20250630_cal.xml (EX-101.CAL) — 51KB
• moln-20250630_def.xml (EX-101.DEF) — 51KB
• moln-20250630_lab.xml (EX-101.LAB) — 222KB
• moln-20250630_pre.xml (EX-101.PRE) — 159KB
• moln-20250630_htm.xml (XML) — 219KB

From the Filing

moln-20250630 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Zrich-Schlieren Switzerland Telephone: +41 447557700 (Address of registrant's principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F EXPLANATORY NOTE Molecular Partners AG (the "Registrant") is filing this Form 6-K to furnish (i) a press release the Registrant issued on August 25, 2024, (ii) its Half year 2025 Strategic Update and Financial Summary and (iii) condensed consolidated interim financial statements (unaudited) as of, and for the three and six months ended, June 30, 2025 (including accompanying notes thereto), which are furnished herewith as Exhibit 99.1, 99.2 and 99.3, respectively. Exhibits 99.1, 99.2, 99.3 and 101 to this Report on Form 6-K, excluding any quotes of management, website addresses or hyperlinks included therein, shall be deemed to be incorporated by reference into the Registrant's Registration Statements on Form F-3 (File No. 333-265960) and Forms S-8 (File No. 333-272974 and File No. 333-280491) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Contents Business Update 4 Financial Summary 9 Results and Overview Financial Highlights Outlook 2025 and Financial Calendar Financial Reports 14 IFRS Condensed Consolidated Interim Financial Statements Auditor's Report on Review of Condensed Consolidated Interim Financial Statements Business Update Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the first half of 2025. "Molecular Partners continues to make good progress towards key development milestones, notably in our two clinical programs. Following the expansion of our strategic radiotherapy partnership with Orano Med in January, we are advancing our lead program MP0712 towards its first-in-human trial. With the data package complete, we anticipate the IND filing and Phase 1 initiation in 2025, and initial clinical data in H1 2026. Our multispecific T cell engager MP0533 is making progress in its Phase 1/2a trial for acute myeloid leukemia. Recently presented data show both increased response rates and greater depth of responses and we look forward to presenting the first data under the amended study protocol in Q4 2025. We also strengthened our leadership with the appointment of Martin Steegmaier, Ph.D., as CSO, further underlining our commitment to delivering improved treatment options for patients and significant value for our stakeholders. Our finances remain robust with funding projected into 2028," said Patrick Amstutz, Ph.D., CEO of Molecular Partners. Research & Development Highlights MP0712 ( 212 Pb x DLL3) , Radio-DARPin Pipeline and Global Partnership with Orano Med The Phase 1 Investigational New Drug (IND) application for MP0712, a 212Pb-based Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3), co-developed with Orano Med for the treatment of small cell lung cancer (SCLC), is in preparation. Molecular Partners presented preclinical data in April at the American Association for Cancer Research (AACR) Annual Meeting 2025, showing a high tumor uptake and a favorable safety profile for MP0712, with good efficacy in mouse models matching clinically relevant DLL3 expression levels. Dialogue with the FDA is ongoing and IND filing expected in Q3 2025. The first clinical sites in the U.S. are identified and, pending regulatory clearance, patient dosing is planned to initiate in 2025 with initial first-in-human clinical data expected in H1 2026. In H1 2025, Molecular Partners accepted a request from Nuclear Medicine Research Infrastructure (NuMeRI) in South Africa to provide MP0712 for imaging use under the legal framework in South Africa for compassionate care (also referred to as Section 21 of the Medicines and Related Substances Act). This approach allows for the potential to generate initial images applying MP0712 labelled with 203Pb in patients with SCLC and other DLL3-expressing neuroendocrine cancers. While the decision of where and how to share data from the image work under Section 21 remains at the discretion of NuMeRI, the Company anticipates providing an update on MP0712 in H2 2025. 203Pb and 212Pb are an element-equivalent pair of lead (Pb) isotopes, with 203Pb p

View Full Filing

View this 6-K filing on SEC EDGAR